Leveraging this innovation, Nuogen Pharma was formed in November of 2018 and is working with experienced partners in the pharmaceutical industry to develop novel JAK inhibitors that can be delivered directly to the nervous system via an intranasal route of delivery. This strategy would allow for maximum e cacy of drug while minimizing hematological side effects that are associated with JAK inhibitors.
The vision for Nuogen Pharma is to be an exclusive anti-itch pharmaceutical company that rapidly brings novel technologies to the highly unmet market of chronic itch. Chronic itch is one of the most common symptoms in all of dermatology and medicine. Therefore, Nuogen Pharma’s mission is to bring soothing relief to millions of patients who suffer from this silent epidemic.
Severe itch can be as debilitating as severe pain. There are few conditions in the house of medicine that cause as much patient suffering with so few options. Ongoing development for drugs like difelikefalin, which is being studied for hemodialysis patients with moderate-to-severe pruritus; nemolizumab, which was granted breakthrough therapy status by the FDA for prurigo nodularis; and JAK inhibitors like those being developed by Nuogen Pharma, offer new and much needed therapeutic options for itch.